These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32469083)

  • 1. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.
    Blasco M; Martínez-Roca A; Rodríguez-Lobato LG; Garcia-Herrera A; Rosiñol L; Castro P; Fernández S; Quintana LF; Cibeira MT; Bladé J; Fernández de Larrea C; Tovar N; Jimenez R; Poch E; Guillen E; Campistol JM; Carreras E; Diaz-Ricart M; Palomo M
    Br J Haematol; 2021 Apr; 193(1):181-187. PubMed ID: 32469083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
    Rassner M; Baur R; Wäsch R; Schiffer M; Schneider J; Mackensen A; Engelhardt M
    BMC Nephrol; 2021 Jan; 22(1):32. PubMed ID: 33461512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
    Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
    J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
    Hobeika L; Self SE; Velez JC
    BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
    Jindal N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Nada R; Sethi J; Ahluwalia J; Malhotra P
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):426-431. PubMed ID: 32735793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Attucci I; Pilerci S; Messeri M; Pengue L; Tomasino G; Caroti L; Vannucchi AM; Antonioli E
    Cancer Rep (Hoboken); 2024 Oct; 7(10):e2163. PubMed ID: 39390755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.
    Catanese L; Link K; Rupprecht H
    BMC Nephrol; 2023 Jun; 24(1):179. PubMed ID: 37337151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study.
    Kozlowski P; Kameran Behnam K; Uggla B; Åström M
    Eur J Haematol; 2020 Jun; 104(6):588-593. PubMed ID: 32115785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab.
    Bhutani D; Assal A; Mapara MY; Prinzing S; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):e155-e157. PubMed ID: 32098724
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy.
    Fang W; Sun W; Fang W; Zhao S; Wang C
    Int Immunopharmacol; 2024 Jun; 134():112178. PubMed ID: 38728883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib: A cause of drug associated thrombotic microangiopathy.
    Qaqish I; Schlam IM; Chakkera HA; Fonseca R; Adamski J
    Transfus Apher Sci; 2016 Jun; 54(3):401-4. PubMed ID: 27017313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement Activation and Thrombotic Microangiopathies.
    Palomo M; Blasco M; Molina P; Lozano M; Praga M; Torramade-Moix S; Martinez-Sanchez J; Cid J; Escolar G; Carreras E; Paules C; Crispi F; Quintana LF; Poch E; Rodas L; Goma E; Morelle J; Espinosa M; Morales E; Avila A; Cabello V; Ariceta G; Chocron S; Manrique J; Barros X; Martin N; Huerta A; Fraga-Rodriguez GM; Cao M; Martin M; Romera AM; Moreso F; Manonelles A; Gratacos E; Pereira A; Campistol JM; Diaz-Ricart M
    Clin J Am Soc Nephrol; 2019 Dec; 14(12):1719-1732. PubMed ID: 31694864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab deposits in vessel walls in thrombotic microangiopathy.
    Cassol CA; Brodsky SV; Satoskar AA; Blissett AR; Cataland S; Nadasdy T
    Kidney Int; 2019 Sep; 96(3):761-768. PubMed ID: 31345584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib-induced thrombotic microangiopathy. A case report.
    Scheggi V; Merilli I; Cesaroni E; Alterini B
    J Oncol Pharm Pract; 2022 Apr; 28(3):754-758. PubMed ID: 34904466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombotic microangiopathy after carfilzomib in a very young myeloma patient.
    Jeyaraman P; Borah P; Singh A; Chhabra GD; Khullar D; Dayal N; Naithani R
    Blood Cells Mol Dis; 2020 Mar; 81():102400. PubMed ID: 31887694
    [No Abstract]   [Full Text] [Related]  

  • 16. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy.
    Moscvin M; Liacos CI; Chen T; Theodorakakou F; Fotiou D; Hossain S; Rowell S; Leblebjian H; Regan E; Czarnecki P; Bagnoli F; Bolli N; Richardson P; Rennke HG; Dimopoulos MA; Kastritis E; Bianchi G
    Blood Cancer J; 2023 Feb; 13(1):31. PubMed ID: 36849497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
    Monteith BE; Venner CP; Reece DE; Kew AK; Lalancette M; Garland JS; Shepherd LE; Pater JL; Hay AE
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e791-e800. PubMed ID: 32807717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
    Camilleri M; Cuadrado M; Phillips E; Wilson W; Jenner R; Pang G; Kamora S; Streetly M; Popat R; Bygrave C; Owen R; Cavenagh J; Chapman M; Sive J; Eccersley L; Sheaff M; Benjamin R; Ramasamy K; Cook G; Virchis A; Chavda SJ; Clifton-Hadley L; Scully MA; Yong K
    Br J Haematol; 2021 May; 193(4):750-760. PubMed ID: 33650100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
    Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension.
    Timmermans SAMEG; Abdul-Hamid MA; Potjewijd J; Theunissen ROMFIH; Damoiseaux JGMC; Reutelingsperger CP; van Paassen P;
    J Am Soc Nephrol; 2018 Aug; 29(8):2234-2243. PubMed ID: 29858281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.